



June 24, 2008

File: 70325-30/omep  
#722921

Ms. Chantal Said  
Associate Provincial Formularies  
Scientific Affairs  
Sandoz Canada Inc.  
145 Jules-Leger Street  
Boucherville QB J4B 7K8

Dear Ms. Said:

Thank you for your submission for the inclusion of **Sandoz Omeprazole, 10mg and 20mg capsules, (omeprazole), DIN 02296438 and DIN 02296446**, as eligible benefits under the PharmaCare Program.

I wish to confirm that these products have been approved and will be eligible for limited coverage (criteria enclosed). Omeprazole 20mg is also subject to PharmaCare's Low Cost Alternative Program (LCA) and will be eligible for partial LCA status, subject to current LCA prices for those clients receiving Special Authority. Upon the effective date of the new LCA booklet, July 28, 2008, Sandoz Omeprazole 20mg will remain a partial LCA benefit. Omeprazole 10mg is currently not included in the Low Cost Alternative Program, but may be considered for inclusion in the future.

Please note that the approval of Sandoz Omeprazole as a benefit is not intended to be a commitment by Pharmaceutical Services to maintain that approval indefinitely, or for any particular period of time. Pharmaceutical Services reserves the right, in its sole discretion, to remove or modify the approval of Sandoz Omeprazole as a benefit for any reason, without first seeking any input. Reasons for which Pharmaceutical Services may remove or modify the approval of Sandoz Omeprazole as a benefit include, but are not limited to economic considerations and/or therapeutic objectives.

The above information will be confirmed in a future issue of the PharmaCare Newsletter. Eligibility of these products will be effective immediately.

Sincerely,

*Original Signed by*

Darlene Arenson, B.Sc. (Pharm) R.Ph  
Director  
Formulary Management  
Drug Intelligence

Enclosure

Ministry of Health

Office of the Director  
Formulary Management  
Drug Intelligence

3-2, 1515 Blanshard Street  
Victoria BC V8W 3C8  
Telephone: 250 952-1183  
Fax: 250 952-2216

Drug Submission # 1744

Drug Submission rec'd: 2007/09/17

IS rec'd: 2008/06/16 11:00am

**Drug Base Update Request Form – for Benefits**

<b>Request Date:</b> 2008/06/16		<b>Effect Date:</b> 2008/06/20		<b>Authorized by:</b> tf/pne/da	
<b>Drug Information:</b>			<b>Manufacturer:</b> Sandoz Canada Inc.		
<b>Brand Name:</b> Sandoz Omeprazole			<b>Chemical / Generic Name:</b> omeprazole		
<b>DIN</b>	<b>Strength</b>	<b>Form</b>	<b>Full Drug Price</b>	<b>Full Quantity (not/unit \$)</b>	
2296438	10mg	capsule	39.37	30 PUP \$1.4042	
2296446	20mg	capsule	37.50	30 PUP \$1.3375	
<b>Therapeutic class of drug/s:</b> 10mg – 564000144, 20mg - 564000141					

**Maximum Days Supply:** Long Term: 0**Flags:**

<b>Trial:</b> No	<b>Trial Days:</b>	<b>Trial Plans:</b>
<b>Triplicate Drug:</b> No	<b>Generic Drug:</b> Yes	<b>RDP Drug:</b> No
<b>Is Din an LCA Drug:</b> Yes (20 mg)	<b>Current LCA Price:</b> 20 mg- 1.3000	
<b>Limited Coverage Drug:</b> Yes	<b>Is DIN eligible for Special Authority?</b> Yes	

**Benefit Groups:****LC (Special Authority)****Category Designation:**

<b>DIN in RDP Category:</b> No	<b>Category:</b>	<b>Sub-Category:</b>
<b>DIN in Non-RDP Category:</b> Yes (20 mg ONLY)	<b>Category:</b> 9901	<b>Sub-Category:</b> 0054
<b>Create new Non-RDP Category / Sub-Category:</b> No		9901 /

**Practitioner Information:**

<b>Practitioner Exemptions:</b> No	<b>Practitioner ID:</b>	<b>ID Ref #:</b>
<b>Assumed SA:</b> No		
<b>Practitioner Specialty Group:</b> Yes	<b>Group ID:</b> M15 – gastroenterologist P70- endoscopists	
<b>Do other DINS exist as Special Authority's for the practitioner specialty group?</b>		Yes

*Note: If DIN exists as a Special Authority and a new Non-RDP Category is to be created, any existing individual DINs will require termination and re-creation under the 'new' Non-RDP Category.*

**Special Instructions:** HIBC: Please add Sandoz-Omeprazole as Limited Coverage drugs, please note practitioner specialty exemption for both strengths.

*Sandoz-Omeprazole 20 mg – please add as partial LCA to omeprazole LCA category. (Note: Upon the effective date of the new LCA Booklet, July 28, 2008, Sandoz Omeprazole 20mg will remain a partial LCA benefit da).*

*Sandoz-Omeprazole 10 mg – please add as a benefit for patients receiving SA. Please create a new LCA category subject to 30 day notification in PharmaCare Newsletter. (Note: new category effective date to be after the LCA Booklet effective date of July 28/08 da)*

*The LCA price will be calculated as follows:*

*Manufacturer's list price + 7% minus 3%. New LCA price will be 0.9081*

*In addition to Sandoz product, also add Losec 10 mg tablet and Losec 10 mg capsule to the new LCA category. Losec 10 mg CAPSULE price decreased effective December 1, 2007 in PharmaNet (manufacturer effective date October 1, 2007) – please take this new price into consideration when creating the category, Losec 10 mg CAPSULE should be full LCA, and Sandoz-Omeprazole 10 mg and Losec 10 mg TABLET should be partial LCA for patients receiving SA.*

*Please also note that only Sandoz-Omeprazole 20 mg should be included in the Non RDP code.*

*Both dins added as Limited Coverage drugs.*

*20mg strength added as a partial with current LCA price of 1.3000 but this has been added to MS Access so will remain a partial in new LCA booklet with new LCA price of 1.1417.*

*10mg strength has been added as a full benefit with SA. New LCA category will be created after new LCA booklet and after 30 days notification in next Newsletter so this change has not been made in MS Access yet. New LCA price for this new category is 0.9081. Losec 10mg tab and Losec 10mg cap will also be added to new LCA category with the caps as full LCA and the other 2 dins partials.*

*Both Dins have been included in Non RDP category. WP*

## Ray, Jessica L HLTH:EX

---

**From:** leonor.ferreira@sandoz.com  
**Sent:** February-12-08 9:17 AM  
**To:** Fazlagic, Tijana HLTH:EX; Emberley, Philip N HLTH:EX  
**Subject:** Re: Sandoz omeprazole

Thank you. Looking forward to talking to Phil on this issue.  
Quick message via Blackberry Wireless

----- Original Message -----

**From:** "Fazlagic, Tijana HLTH:EX" [Tijana.Fazlagic@gov.bc.ca]  
**Sent:** 02/12/2008 08:32 AM PST  
**To:** Leonor Ferreira; "Emberley, Philip N HLTH:EX" <[Philip.Emberley@gov.bc.ca](mailto:Philip.Emberley@gov.bc.ca)>  
**Subject:** RE: Sandoz omeprazole

Hello Leonor,

I am forwarding your question to Phil Emberley, a pharmacist that deals with generic drug submissions.

Regards,  
Tijana F.

Tijana Fazlagic , B.Sc.(Pharm), MSc  
Pharmacist Consultant  
Formulary Management  
Pharmaceutical Services  
(250) 952-1475  
[Tijana.Fazlagic@gov.bc.ca](mailto:Tijana.Fazlagic@gov.bc.ca)

-----Original Message-----

**From:** leonor.ferreira@sandoz.com [<mailto:leonor.ferreira@sandoz.com>]  
**Sent:** Tuesday, February 12, 2008 7:58 AM  
**To:** Fazlagic, Tijana HLTH:EX  
**Subject:** Sandoz omeprazole

Hi Tijana,  
Now that my BC group has gotten over the joy of the Sandoz enalapril listing with Pharmacare they are anxiously (they are pestering me in fact)awaiting news/developments on status for Sandoz omeprazole....

Do you have any idea when that review will be completed. This file has been there a long time. Are there any issues we need to address to move

things along?

I can be reached this afternoon pacific time at 514 889 2161. Thanks and have a great day!

Best regards,

Leonor

Quick message via Blackberry Wireless